Background: ADAPT-DES was a prospective, multicenter, real-world registry of 8,583 consecutive pts at 11 international centers undergoing percutaneous coronary intervention (PCI) with DES designed to determine the frequency, timing, and correlates of early and late stent thrombosis (ST). Treatment of bifurcation lesions has been shown to be associated with an increased risk of ST and worse clinical outcome. We therefore analyzed the impact of bifurcation PCI on outcomes at 1 year. Methods: Univariable and a fully adjusted multivariable analysis including propensity score stratification were performed to determine the relationship between bifurcation PCI and subsequent events. Results: During the index procedure, bifurcation lesions were treated in 1,317 (15.7%) of 8,583 pts. Pts in the bifurcation group were less likely to be female (22.2% vs. 26.6%, p<0.001), diabetic (28.2% vs. 33.2%, p<0.001), or have ACS (47.2% vs. 52.5%, p<0.001). Post-procedure platelet reactivity was lower among patients undergoing bifurcation PCI (mean P2Y12 PRU 183 vs. 189, p¼0.017). Pts with bifurcation PCI had more total stents (2.10 vs. 1.65, p<0.0001) resulting in longer total stent length (39.2 vs. 31.2 mm, p<0.0001). Bifurcation lesions were more often in LAD territory (48.9% vs. 37.0%, p<0.0001). Both branches were stented in 19.1% of all bifurcation lesions, and final kissing was done in 46.1%. The 1 year unadjusted rates of adverse outcomes are shown in the Table. In propensity adjusted models, bifurcation treatment was not independently associated with 1-year MACE (HR [95% CI] ¼ 1.13 [0.89, 1.42, p¼0.32), cardiac death (0.75 [0.31, 1.54], p¼0.43), ST (0.64 [0.30, 1.36], p¼0.24), or TVR (1.13 [0.89, 1.43], p¼0.31).
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Background: POLBOS is the randomized, prospective, multicentre study planned to compare two intervention strategies for bifurcation treatment: provisional T-stenting (PTS) with any regular drug-eluting stent (DES) and dedicated bifurcation paclitaxeleluting stent BiOSS Expert (Balton, Poland). Methods: Between September 2010 and December 2012 in four centers in Poland patients with stable CAD or NSTE-ACS were randomized to the group where BiOSS Expert was implanted or to the group where regular DES was used. An angiographic control was planned at 12 months in all patients. The primary end-point of the study is the rate of death, MI, ST and TLR after 12 months. At the time of TCT 2013 complete clinical 9-month follow-up will be available as well as 90% of angiographic controls after 12 months. Results: BiOSS Expert was implanted in 119 patients (49.4%) and regular DES was implanted in 122 patients (50.6%). The average age of patients did not differ significantly between groups (BiOSS vs DES: 66.5 vs 66.8 yrs). In BiOSS group there were significantly more patients with NSTE-ACS (9.6% vs 3.5%), diabetes (32.2% vs 16.8%), prior MI and prior CABG. In DES group there were more patients addicted to smoking (13% vs 22.1%). The dominant vessel was LAD (BiOSS vs DES: 52.1% vs 70.5%) followed by LMS (22.7% vs 13.9%, respectively). In DES group 35.4% of stents eluted paclitaxel (PES). There were following nominal stent parameters in BiOSS group: 3.69AE0.36mm x 2.99AE0.36mm x 16.96AE1.44mm and in DES group: 3.27AE0.49mm x 20.6AE6.96 mm. Except for 2 (1.64%) cases in DES group and 1 (0.84%) in BiOSS group all stents were implanted successfully. There were 16% (BiOSS) and 11.2% (DES) cases with second stent implanted within the side branch. At six months all patients were uneventful. Up to now control angiography was performed in 76% of patients in BiOSS group and in 74% in DES group. TLR was, respectively, 10.99% vs 8.9% (p ¼ 0.5). Nevertheless, within DES group TLR in PES subgroup was 12.8% and in -olimus subgroup -5.7% Conclusions: 9-month follow-up showed that BiOSS Expert provides satisfactory results which seem to be inferior to those obtained by means of -limus eluting stents, but comparable with those of PES. Background: The provisional T-stenting (PTS) is the recommended strategy for the coronary bifurcation treatment. However, results obtained with use of regular drug eluting stents (DES) are not optimal and relatively often associated with a side branch compromise and restenosis. Dedicated bifurcation stents are claimed to be a solution for these complications. POLBOS II study is the continuation of POLBOS study, which paclitaxel-eluting stent BiOSS Expert was assessed in. Methods: It is a randomized multicenter study planned to compare two strategies for the bifurcation treatment -PTS with any regular DES or with a dedicated bifurcation sirolimus-eluting stent BiOSS LIM (Balton, Poland) in patients with CAD or NSTE-ACS. An angiographic control was planned at 12 months in all patients. The primary end-point of the study is the rate of death, MI, ST and TLR after 12 months. The aim is to enroll 120 patients (60 in each group). Results: The enrollment started in November 2012. To date, 75 patients (64% males) were randomized (40 in BiOSS group, 35 in DES group). The average age was 64AE9 yrs. The dominant vessel was LAD (50%) followed by LMS (33%). 72% of cases were true bifurcations. All stents were implanted successfully. There were 12.5 and 14.3% of Background: There is uncertainty about influence of periprocedural ischemia and myonecrosis on long-term results of coronary artery bifurcation stenting (PCI). Restenosis remains an unresolved issue, and identification of its predictive factors may allow further insight into the underlying process. The aim of the study is to explore the influence of end-procedural ischemia (detected with intracoronary electrocardiography (icECG) and post-procedural myonecrosis (troponin and creatinephosphokinase -MB (CK-MB) elevation) on revascularization rates (TLR) at 12 months after PCI. Methods: After placement of intracoronary guidewires in main branch (MB) and side branch (SB) an uninsulated proximal ends of wires were connected to unipolar V leads. Intracoronary unipolar ECGs (icECG) were recorded before, during and after stent placement and at the end of procedure. The maximal ST-segment elevation during intervention and 5 min after the procedure was recorded in SB and MB. Results: We studied 142 patients with different types of bifurcation lesions with stable/unstable angina: 69% were males, mean age 69AE9, diabetics 33.6%. The main treated vessel was LAD (77%). True bifurcation lesions (Medina xx1) were 53%. 131 (92%) patients were followed for more than 12 months. The TLR at 12 months of follow-up was 7.6% (10/131 Conclusions: The end-procedural ischemia detected by intracoronary ECG in the main branch territory is a sensitive newly discovered factor for prediction of in-stent restenosis after coronary bifurcation stenting.
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Excellent results after treatment of de novo bifurcation lesions with DCB only strategy Results: Age was 71.3AE8.8 years old, male gender is 42 (66.7%), diabetes mellitus is 8 (12.7%), and hemodialysis (HD) is 13 (20.6%). Mean EuroScore was 5.60 and SYNTAX score was 35.5%. There is no peri-procedural death and perforation, while peri-procedural MI occurred in 6 (9.5%). At 1-year, cardiac-death occurred in 5 (7.9%) patients and TLR occurred in 16 (25.4%). Notably, TLR-MB occurred in 9 (14.3%) and was more frequently observed in HD patients as compared to non hemodialysis (non HD) patients (38.5% vs. 4.0%, p¼0.001). IVUS finding demonstrated the majority of patients achieved optimal stent expansion with MSA above 8.2cm2 at LM and above 6.3 cm2at proximal LAD. However, TLR-MB was necessary in 5 (7.9%) patients on HD despite optimal stent expansion.
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